Pulmonary
Partner With Us
Advertisement
Conexiant chevron_right Pulmonary chevron_right Tezepelumab Shows Promise for Severe CRSwNP in Phase 3 Trial
From the Journals

Tezepelumab Shows Promise for Severe CRSwNP in Phase 3 Trial

The WAYPOINT trial provides strong evidence that tezepelumab effectively reduces nasal polyp size, congestion, and overall symptom burden in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

Conexiant
article Full Article subject Summary summarize Notecard
A new study published in the New England Journal of Medicine demonstrates that tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, significantly reduces nasal polyp size, congestion, and overall symptom burden in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps. The phase 3 WAYPOINT trial shows that tezepelumab leads to improvements in sinonasal symptoms and reduces the need for nasal polyp surgery and systemic glucocorticoid use. This research offers strong evidence supporting the potential expanded use of tezepelumab beyond asthma to effectively target CRSwNP at its inflammatory source.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.